This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

October 25–28, 2021
Delivered DigitallyCentral European Time

Sunil Shah
CEO at o2h Group

Profile

Sunil Shah is the CEO of the o2h Group which has developed an engine for seeding a pipeline of early
stage life science assets through research collaborations, in-licensing, spin-outs & investments. The DNA
of o2h is centred around the nurturing of its people, values and culture, it reflects in the way we work with
each other, as well as our collaborators and partners. In 2019, Sunil won the UKBAA Angel Investor of
the Year Award as well as the OBN Special Recognition Award for his contribution to the life sciences
industry in the UK.


Sunil is a Board Director of Cambridge Angels and also is a member of the Advisory Panel of Cancer
Research UK (CRUK) which is the UK’s largest cancer research charity. He is also a non-executive
director in the Board of Bioindustry Association Ltd. (BIA). He is either Chairman, Director, Board
Observer or investor of: Phoremost, Exonate, Opal Oncology, Five Alarm Bio, Somaserve, DeepMatter,
Oppilotech, Sentinel, Small Pharma, Arecor, Metrion, Talisman, Stemnovate, Acacia, Privitar and Oxford
Drug Design. Sunil has a degree in Biochemistry and an MBA from Cambridge University.

Agenda Sessions

  • Startup Slam

    15:00